THEOCHARIS ANASTASIOU

Dr. THEOCHARIS ANASTASIOU

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
TATHEOCHARIS ANASTASIOU
THEOCHARIS ANASTASIOU
ESElias Sanidas
Elias Sanidas
TLThekla Lytra
Thekla Lytra
GMGeorgios Mimikos
Georgios Mimikos
HGHelen Gogas
Helen Gogas
MMMarina Mantzourani
Marina Mantzourani
The association between COVID-19 vaccination and thromboembolic events has garnered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca’s and Johnson & Johnson’s vaccines. This review underscores the uncommon occurrence of venous thromboembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT) following COVID-19 vaccination. Although these complications are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. In addition, rare renal complications such as acute kidney injury and thrombotic microangiopathy have been documented, broadening the spectrum of potential vaccine-associated thrombotic manifestations. Current guidelines emphasize early detection, individualized risk assessment, and use of anticoagulation therapy to mitigate risks. Despite these events, the overwhelming majority of evidence supports the continued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. In addition, recent comparative data confirm that mRNA-based vaccines are associated with a significantly lower risk of serious thrombotic events compared to adenoviral vector platforms. Ongoing research is essential to further refine preventive and therapeutic strategies, particularly for at-risk populations.

8 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TATHEOCHARIS ANASTASIOU
THEOCHARIS ANASTASIOU
ESElias Sanidas
Elias Sanidas
TLThekla Lytra
Thekla Lytra
PKPanagoula Kollia
Panagoula Kollia
HGHelen Gogas
Helen Gogas
MMMarina Mantzourani
Marina Mantzourani
The association between COVID-19 vaccination and thromboembolic events has gar-nered significant research attention, particularly with the advent of vaccines based on adenoviral vectors, including AstraZeneca's and Johnson & Johnson's. This review un-derscores the uncommon occurrence of blood clotting events, including venous throm-boembolism (VTE), arterial thromboembolism (ATE), and vaccine-induced thrombotic thrombocytopenia (VITT), following COVID-19 vaccination. Although these complica-tions are extremely rare compared to the heightened risk of thrombosis from COVID-19 infection, elements like age, biological sex, type of vaccine and underlying health conditions may contribute to their development. Current guidelines emphasize early detection, individualized risk assessment, and the use of anticoagulation therapy to mitigate risks. Despite these rare events, the overwhelming evidence supports the con-tinued use of COVID-19 vaccines, given their proven efficacy in reducing severe illness and mortality. Ongoing research is essential to further refine preventive and therapeu-tic strategies, particularly for at-risk populations.